Clinical Trial Update: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating tinengotinib versus physician's choice for FGFR-altered cholangiocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Tinengotinib (tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Cholangiocarcinoma | Phase 3 | Status: RECRUITING